VIVORYON THERAPEUTICS NV (VVY.AS) Stock Price, Forecast & Analysis
Europe - Euronext Amsterdam - AMS:VVY - NL00150002Q7 - Common Stock
VVY.AS Key Statistics, Chart & Performance
The current stock price of VVY.AS is 1.46 EUR. In the past month the price decreased by -8.75%. In the past year, price decreased by -28.08%.
VVY.AS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 68.21 | 44.30B | ||
| ARGX.BR | ARGENX SE | 68.11 | 44.24B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 18.82B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.96B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.31B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.85B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.84B | ||
| NANO.PA | NANOBIOTIX | N/A | 939.24M | ||
| 5CV.DE | CUREVAC NV | 6.1 | 796.20M | ||
| IVA.PA | INVENTIVA SA | N/A | 725.87M | ||
| PHIL.MI | PHILOGEN SPA | 20.26 | 675.44M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
Related stock screener links
About VVY.AS
Company Profile
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 14 full-time employees. The company went IPO on 2014-10-27. The firm has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. The company focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
Company Info
VIVORYON THERAPEUTICS NV
Weinbergweg 22
HALLE SACHSEN-ANHALT DE
Employees: 14
Phone: 493455559900
VIVORYON THERAPEUTICS NV / VVY.AS FAQ
What does VIVORYON THERAPEUTICS NV do?
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 14 full-time employees. The company went IPO on 2014-10-27. The firm has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. The company focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
What is the current price of VVY stock?
The current stock price of VVY.AS is 1.46 EUR. The price decreased by -1.35% in the last trading session.
What is the dividend status of VIVORYON THERAPEUTICS NV?
VVY.AS does not pay a dividend.
What is the ChartMill technical and fundamental rating of VVY stock?
VVY.AS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is VVY.AS stock listed?
VVY.AS stock is listed on the Euronext Amsterdam exchange.
How is the market expecting VVY stock to perform?
7 analysts have analysed VVY.AS and the average price target is 4.93 EUR. This implies a price increase of 237.67% is expected in the next year compared to the current price of 1.46.
VVY.AS Technical Analysis
VVY.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS. While VVY.AS seems to be doing ok healthwise, there are quite some concerns on its profitability.
VVY.AS Financial Highlights
Over the last trailing twelve months VVY.AS reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 60% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.39% | ||
| ROE | -392.45% | ||
| Debt/Equity | 0 |
VVY.AS Forecast & Estimates
7 analysts have analysed VVY.AS and the average price target is 4.93 EUR. This implies a price increase of 237.67% is expected in the next year compared to the current price of 1.46.